<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615910</url>
  </required_header>
  <id_info>
    <org_study_id>20201013</org_study_id>
    <nct_id>NCT04615910</nct_id>
  </id_info>
  <brief_title>A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass</brief_title>
  <acronym>Ver-A-image</acronym>
  <official_title>A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bart's London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the trial is to measure pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for&#xD;
      detection of intra-individual differences in beta cell mass before and after treatment with&#xD;
      Verapamil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VER-A-T1D (Verapamil SR in adults with Type 1 Diabetes) study is an intervention study&#xD;
      within the INNODIA project (an Innovative Medicines Initiative consortium (IMI-2),&#xD;
      established through Horizon 2020 initiative of the European Union, involving academic,&#xD;
      industry and charitable partners).&#xD;
&#xD;
      In the VER-A-T1D study, the effects of treatment of newly diagnosed patients with T1D with&#xD;
      Verapamil will be evaluated. Verapamil appears to protect beta cell function, an effect that&#xD;
      could in part be caused by protection against beta cell apoptosis. GLP-1 receptors are&#xD;
      expressed in high densities in beta cells. Exendin, a GLP-1 receptor agonist, can be labeled&#xD;
      with radionuclides and thus be utilized for visualization of beta cells in vivo by positron&#xD;
      emission tomography (PET). This technology has been demonstrated to deliver quantitative&#xD;
      information of the radiotracer uptake in the pancreas demonstrating a linear correlation with&#xD;
      beta cell mass. In VER-A-T1D, we propose to measure beta cell mass at the time points of&#xD;
      inclusion and at evaluation after 12 months. If verapamil protects beta cells against&#xD;
      apoptosis, we expect that the uptake of the radiotracer will be higher at 12 months in&#xD;
      comparison to the first measurement in the treatment group. The study will be a substudy to&#xD;
      VER-A-T1D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Type 1 Diabetes Mellitus</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic 68Ga-exendin uptake</measure>
    <time_frame>Change from time of inclusion to 12 months into treatment</time_frame>
    <description>the total pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for determination of beta cell mass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of 68Ga-exendin uptake and C-peptide</measure>
    <time_frame>12 months into treatment</time_frame>
    <description>• Changes in 68Ga-NODAGA-exendin pancreas uptake in realtion to changes in C-peptide measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative 68Ga-exendin uptake</measure>
    <time_frame>12 months into treatment</time_frame>
    <description>• Differences in 68Ga-NODAGA-exendin uptake between individuals and between the two timepoints of imaging intra-individually</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Verapamil within the Ver-A-T1D trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with placebo within the Ver-A-T1D trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-NODAGA-exendin-4 PET/CT</intervention_name>
    <description>68Ga-NODAGA-exendin-4 PET/CT</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Have given written informed consent&#xD;
&#xD;
          -  • Age ≥18 and &lt;45 at consent&#xD;
&#xD;
          -  • Must have a diagnosis of T1D of within 6 weeks duration at screening (date of the&#xD;
             first insulin&#xD;
&#xD;
          -  injection)&#xD;
&#xD;
          -  • Must have at least one or more diabetes-related autoantibodies present at screening&#xD;
&#xD;
          -  • Must have random C-peptide levels ≥200 pmol/L measured at screening&#xD;
&#xD;
          -  • Be willing to comply with intensive diabetes management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV&#xD;
             inhibitors (to exclude interferences with imaging, specifically mentioned although in&#xD;
             principle part of exclusion criteria of VER-A-T1D)&#xD;
&#xD;
          -  Renal disease defined as MDRD &lt;40 ml/min/1.73 m2&#xD;
&#xD;
          -  Pregnancy or the wish to become pregnant within 2 months after the second PET/CT scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Verapamil</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>exendin</keyword>
  <keyword>Beta cell mass</keyword>
  <keyword>PET imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

